[1]周 旭.乙肝清热解毒颗粒治疗慢性乙型病毒性肝炎临床观察[J].西部中医药,2017,30(11):103-106.
　ZHOU Xu.Clinical Observation of Hepatitis B Heat-clearing Detoxifcation Granules in Treating Chronic Viral Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2017,30(11):103-106.
点击复制

乙肝清热解毒颗粒治疗慢性乙型病毒性肝炎临床观察()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
30
期数:
2017年11期
页码:
103-106
栏目:
出版日期:
2017-11-15

文章信息/Info

Title:
Clinical Observation of Hepatitis B Heat-clearing Detoxifcation Granules in Treating Chronic Viral Hepatitis B
文章编号:
1004-6852(2017)11-0103-04
作者:
周 旭
中国医科大学附属第一医院传染科，北京 110000
Author(s):
ZHOU Xu
Department of Infectious Disease, The First Hospital of China Medical University, Beijing 110000, China
关键词:
乙型病毒性肝炎; 慢性传染病; 乙肝清热解毒颗粒
Keywords:
viral hepatitis B;  chronic infectious disease;  hepatitis B heat-clearing detoxifcation granules
分类号:
R242
摘要:
目的：观察乙肝清热解毒颗粒治疗慢性乙型病毒性肝炎的临床疗效。方法：将慢性乙型病毒性肝炎患者72例随机分为2组，对照组35例予常规西医治疗，研究组37例在对照组治疗的基础上予乙肝清热解毒颗粒治疗，疗程为8周，比较2组治疗前后临床症状及各指标变化情况。结果：治疗前，2组患者胁痛、头晕耳鸣、腰膝酸软、少寐多梦和五心烦热症状比较差异无统计学意义(P＞0.05)；治疗8周后研究组患者胁痛、头晕耳鸣、腰膝酸软、少寐多梦和五心烦热症状的发生率明显低于对照组(P＜0.05)。治疗前2组患者丙氨酸转氨酶(ALT)水平、HBV-DNA载量和HBeAg滴度比较差异无统计学意义(P＞0.05)，治疗后2组ALT水平、HBV-DNA载量和HBeAg滴度均降低，且研究组低于对照组(P＜0.05)。治疗后对照组HBV-DNA转阴率为51.43%，HBsAg转阴率为0.00%，HBeAg转阴率为17.14%；研究组HBV-DNA转阴率为72.97%，HBsAg转阴率为2.70%，HBeAg转阴率为24.32%。研究组各指标的转阴率高于对照组(P＜0.05)。治疗后对照组显效20例(57.14%)，有效7例(20.00%)，无效8例(22.86%)，总有效27例(71.43%)；研究组显效29例(78.38%)，有效6例(16.22%)，无效2例(5.41%)，总有效35例(94.59%)。研究组总有效率高于对照组(P＜0.05)。结论：乙肝清热解毒颗粒联合西医常规治疗能明显改善慢性乙型病毒性肝炎患者的临床症状，提高转阴率，改善肝功能。
Abstract:
Objective: To investigate the clinical effects of hepatitis B heat-clearing detoxifcation granules in the treatment of chronic viral hepatitis B. Methods: Seventy-two patients were randomized into 35 cases of the control group, who accepted routine treatment of western medicine, and 37 cases of the experiment group, who took hepatitis B heat-clearing detoxifcation granules on the foundation of the treatment and the care the control group received, the course was eight weeks, the changes of different indexes and clinical symptoms of both groups were compared before and after treating. Results: Before treating, the difference had no statistical meaning in the comparisons of hypochondriac pain, dizziness and tinnitus, soreness and weakness of waist and knee, insomnia and dreaminess, dysphoria with feverish sensation in chest, palms and soles between both groups (P＞0.05); after treating for eight weeks, the experiment group was lower than the control group in the incidence of hypochondriac pain, dizziness and tinnitus, soreness and weakness of waist and knee, insomnia and dreaminess, dysphoria with feverish sensation in chest, palms and soles (P＜0.05). The difference had no statistical meaning in the comparisons of ALT level, HBV-DNA capacity and HBeAg titer between both groups before treating (P＞0.05), ALT level, HBV-DNA capacity and HBeAg titer in both groups lowered after treating, and the experiment group was lower than the control group (P＜0.05). After treating, HBV-DNA negative-conversion rate of the control group was 51.43%, HBsAg negative-conversion rate was 0.00%, HBeAg negative-conversion rate was 17.14%; while HBV-DNA negative-conversion rate of the experiment group was 72.97%, HBsAg negative-conversion rate was 2.70%, HBeAg negative-conversion rate was 24.32%. The experiment group was higher than the control group in the negative-conversion rate of different indexes (P＜0.05). After treating, in the control group, there were 20 cases markedly effective (57.14%), seven cases effective (20.00%), eight cases (22.86%) and total effective 27 cases (71.43%); in the experiment group, 29 cases markedly effective (78.38%), six cases effective (16.22%), two cases (5.41%) and total effective 35 cases (94.59%). The experiment group was higher than the control group notably in total effective rate (P＜0.05). Conclusion: Hepatitis B heat-clearing detoxifcation granules jointed with routine treatment of western medicine could significantly improve clinical symptoms, raise negative-conversion rate and improve liver function in the treatment of chronic viral hepatitis B.

相似文献/References:

[1]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(11):149.

备注/Memo

备注/Memo:
收稿日期：2016-10-30 作者简介：周旭(1983—)，女，护师。研究方向：传染病。
更新日期/Last Update: 2017-11-15